PRRT2 and glioblastoma: For the treatment of GBM, Couldwell and colleagues and Brandes and colleagues were the first to use high-doses of tamoxifen to inhibit PKC, based on in vitro assays that evaluated apoptosis in GBM cells either alone, or in combination with procarbazine in phase II clinical trials.